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Abstract The disulphide bond pattern of the long disintegrin 
bitistatin (83 aniino acids, 14 cysteines) was established using 
structural information gathered by aniino acid analysis, N-
terminal sequencing, and molecular mass determination of 
fragments isolated by reversed-phase HPLC after polypeptide 
degradation with trypsin and oxalic acid. A computer program 
was used to calculate all possible combinations of disulphide-
bonded peptides matching the mass spectrometric data, and the 
output was filtered using compositional and sequence data. 
Disulphide bonds between cysteines 16-34,18-29, 28-51, 42-48, 
47-72, and 60-79 are conserved in medium-long disintegrins 
flavoridin and kistrin (70 amino acids, 12 cysteines), and the two 
cysteine residues at positions § and 24 found in bitistatin but not 
in other disintegrin molecules are disulphide-bridged. This 
linkage creates an extra, large loop, which, depending on 
whether the NMR structure of flavoridin or kistrin is used for 
modelling the structure of bitistatin, lies opposite or nearly 
parallel, respectively, to the biologically active RGD-containing 
loop. 
© 1997 Federation of European Biochemical Societies. 
Key words: Disulfide bond; Disintegrin; Bitistatin; 
RGD peptide; Snake venom; Mass spectrometry; 
Oxalic acid degradation 
1. Introduction 
Snake venoms contain a complex mixture of pharmacolog-
ically active peptides and proteins. Disintegrins are low mo-
lecular mass (5-9 kDa), cysteine-rich peptides isolated from 
the venom of Viperidae and Crotalidae snake species, which 
exert their biological activities by competing with, and pre-
venting, the binding of adhesive ligands to integrin receptors 
(reviewed in [1,2]). Since the early characterisation of the first 
two disintegrins, trigramin and echistatin, from the venoms of 
Trimeresurus gramineus [3] and Echis carinatus [4], respec-
tively, more than 40 disintegrins have been isolated from viper 
and rattlesnake genera [1,3,5]. Disintegrins appear to use a 
common inhibitory mechanism involving the (R/K)GD tri-
peptide integrin-binding motif [6] presented at the tip of a 
highly mobile loop in the NMR solution structure of echista-
tin [7-9], kistrin [10], flavoridin [11], and albolabrin [12]. The 
activity of disintegrins depends on the appropriate pairing of 
eight to 14 cysteines by disulphide bridges, which maintain the 
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RGD-containing loop in its active conformation [13]. How-
ever, primary structure characteristics and conformational 
features modulate their potency and receptor selectivity. 
Thus, replacement of RGD with KGD in barbourin imparts 
greater selectivity for integrin 0Cnbß3 [14], and disintegrins dis-
playing the sequence RGDNP in their active loop inhibit 
more strongly the binding of fibronectin and vitronectin to 
integrins 065 ßi and ocvß3, respectively, than fibrinogen binding 
to integrin 0Cnbß3 [15]. On the other hand, those disintegrins 
having the sequence RGDW are twice as effective in blocking 
the binding of fibrinogen to 0Cnbß3 than inhibiting the binding 
of vitronectin to integrin Ovß3 [15]. 
Investigations on the selective recognition of disintegrins 
with limited variation in their RGD sequence environment 
[16] and cyclic RGD peptides with defined NMR solution 
conformation by integrins ocsßi, ovß3, and ocnbß3 [17], along 
with molecular modelling studies [18], led to the concept that 
the shape and size of the RGD loop are important structural 
features that affect fitting of the ligand to the binding pocket 
of integrin receptors. For instance, the RGD loops of eristo-
statin and mutant echistatin D27W are wider than that of 
wild-type echistatin due to the placement of tryptophan 
(rather than aspartic acid) immediately after the RGD se-
quence, and this results in an increase of anti-ocnbß3 and a 
decrease of anti-oivßs activity. The Coc distances between R 
and X in the RGDX sequences of echistatin, eristostatin, and 
D27W echistatin are 5.8, 8.2, and 8.5 Á, respectively [18]. 
Substitution of R22 with V in echistatin further alters the 
shape of the RGD loop of this disintegrin and increases its 
affinity to 0Cnbß3 [19]. However, the disintegrin eristostatin 
binds with higher affinity to resting platelets than bitistatin 
despite the fact that both display the same sequence 
(RGDWN) within their active loops [20], indicating that fac-
tors other than the RGDX sequence may determine the spe-
cificity and potency of disintegrins. In this context, the solu-
tion structures of echistatin [7-9], flavoridin [11], and 
albolabrin [12] show that the C-terminal regions are in close 
proximity to their respective RGD-containing loops, and 
Gould et al. showed that deletion of the sequence PRPN 
from the C-terminal region of echistatin reduced the ability 
of the disintegrin to inhibit platelet aggregation [21]. Chemical 
synthesis of echistatin analogues showed that the C-terminal 
peptide does not influence the folding of the disintegrin to its 
biologically active structure [22]. The synthetic C-terminal 
peptide of echistatin inhibited binding of echistatin, but not 
of fibrinogen, to integrin c<nbß3 [23]. Recently, Marcinkiewicz 
et al. [24] have shown that echistatin's C-terminal polypeptide 
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4 2 N P H K G P A T 4 9 induces conformational changes on integ-
rals 0Cyß3 and (Xnbß3 and potentiates the inhibitory effect of 
echistatin in a non-specific way. These data suggest for the 
C-terminal tail of echistatin, and perhaps of other disintegrins, 
a synergistic or helper biological role distinct from the R G D 
motif, the primary, selective integrin recognition site. 
A salient feature of disintegrins is their high relative content 
of disulphide bonds and that the disulphide bridge pat tern is 
not absolutely conserved among short ( ~ 50 residues, four 
disulphide bonds) and medium-long ( ~ 70 amino acids cross-
linked by six disulphide linkages) disintegrins [13,18,25]. Fur-
thermore, a mutan t echistatin molecule with enhanced inhib-
ition activity of the binding of human fibrinogen to its platelet 
receptor has been constructed by constraining the conforma-
tion of the active loop through engineering of an extra disul-
phide bridge between cysteines located at the N - and C-termi-
ni of the R G D sequence ( C R G D Ç ) [26]. Hence, variation in 
cystine linkages may represent another variable modulat ing 
the activity of the RGD-containing loop. Here we report 
the disulphide bridge pattern determination of bitistatin, a 
long (83-84 residues and seven disulphides) disintegrin. 
2. Materials and methods 
2.1. Isolation of bitistatin 
Bitistatin was purified to homogeneity from the crude venom of 
Bitis arietans (Latoxan, France) using one-step reversed-phase 
HPLC essentially as described [27]. Briefly, 1 mg of crude venom 
was dissolved in 0.1% (v/v) trifluoroacetic acid, and centrifuged at 
13000Xg to remove particulate matter. The venom proteins were 
separated on a Vydac (Hesperia, CA, USA) C18 (250x4 mm, 5 |xm 
particle size) column eluting with an acetonitrile gradient. Fractions 
were tested for inhibitory activity in platelet aggregation using 20 uM 
ADP as agonist. 
2.2. Protein cleavages and isolation of fragments 
Bitistatin (2-5 mg/ml in 20 mM sodium phosphate, 150 mM NaCl, 
pH 6.8) was degraded with TPCK-trypsin (Sigma) at an enzyme:sub-
strate ratio of 1:100 (w/w) for 4 h at 37°C. Bitistatin (10 mg/ml in 
water) was also degraded with 250 mM oxalic acid [18,28] (final con-
centration) for 18 h at 100°C. Tryptic and oxalic acid-derived frag-
ments were isolated by reversed-phase HPLC on a Lichrospher RP100 
C18 (250x4 mm, 5 |xm pore size) column eluting at 1 ml/min with 
0.1% (v/v) trifluoroacetic acid in water (solution A) and acetonitrile 
(solution B). Peptides were eluted isocratically (5% B) for 5 min, 
followed by a gradient of 5-50% B for 90 min, and 50-70% B for 
20 min. Elution was monitored by UV absorption at 220 nm, and 
Chromatographie fractions were collected manually. 
2.3. Characterisation of fragments 
Tryptic peptides and oxalic acid-derived fragments were subjected 
to amino acid analysis using a Pharmacia AlphaPlus analyser (after 
sample hydrolysis with 6 M HC1 at 110°C for 18 h in evacuated and 
sealed ampoules) and N-terminal amino acid sequence analysis (using 
an Applied Biosystems Procise 494 instrument). Molecular masses of 
oxalic acid-derived fragments (native or reduced with 2-mercaptoefha-
nol at 100°C for 2 min) were determined by matrix-assisted laser/ 
desorption ionisation (MALDI) time-of-flight (TOF) mass spectrom-
etry with a LaserTec RBT II (PerSeptive Biosystems/Vestec, Houston, 
TX, USA) run in linear mode. Samples were prepared by the dried 
droplet method [29] after mixing on the plate 1 ul of HPLC fractions 
and 1 |xl of matrix solution (5 mg/ml a-cyano-4-hydroxycinnamic acid 
and 5 mg/ml L-fucose in 50% (v/v) acetonitrile containing 0.1% (v/v) 
trifluoroacetic acid). For spectra acquisition, positive ions were accel-
erated at 25 kV and up to 30 laser shots were automatically accumu-
lated. The time-of-flight mass data were externally calibrated using a 
mixture of peptides of known molecular masses. Collision-induced 
fragmentation was accomplished by electrospray ionisation mass spec-
trometry using an API III+ (Sciex, Thornhill, Ont., Canada) MS/MS 
triple quadrupole spectrometer. Typical experimental conditions were 
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collision gas (argon) thickness of 3-4 X 1014 molecules/cm2 and colli-
sion energy of 20-40 eV. 
2.4. Assignment of disulphide bond combinations 
All theoretical fragments containing two disulphide-bonded pep-
tides were calculated with the program DISULPHIDE [30] using 
the experimental MALDI mass spectrometry data ( ± 1 Da) as input. 
The primary outputs were filtered manually taking into consideration 
information gathered from amino acid analysis and/or N-terminal 
sequencing. 
2.5. Homology modelling of bitistatin 
Three-dimensional models of bitistatin were built on the basis of 
kistrin and flavoridin coordinates determined by NMR studies [10,11] 
(PDB accession codes 1KST and 1FVL, respectively). Residues 
^PPVCGNKILEE12 and 24CQD26 of bitistatin were incorporated 
in the structures of kistrin and flavoridin, a disulphide bond between 
Cys5 and Cys24 was created, the models were optimised for stereo-
chemistry, and then refined by energy minimisation using XPLOR 
[31]. The energy minimised structures were heated at 1500 K and 
were further refined with a slow cooling simulated annealing molec-
ular dynamics protocol using XPLOR. 
3. Results and discussion 
3.1. The disulphide bond pattern of bitistatin 
Degradation of bitistatin with TPCK-trypsin generated two 
H P L C peptide fractions (F l and F2) containing cysteine, as 
revealed by amino acid analysis, which were characterised by 
N-terminal sequence analysis. The F l sequence displayed two 
phenylthiohydantoin (PTH)-amino acids in cycles 1-3 and 6: 
(A,S) (G,S), (T,D), V, P, (R,W), N , H, which, based on the 
known primary structure of bitistatin [32], were interpreted as 
polypeptide stretches 58-61 and 76-83 held together by a 
disulphide bond between Cys60 and Cys79 (Fig. 1). The struc-
ture of F2 was more complex showing three or four residues 
in each Edman degradation cycle: (S,L,G), (T,P,D), (P,N,W), 
(N,A,V,G), (A,D,S), (G,T,Q,D). The four amino acid sequen-
ces were assigned to the polypeptide stretches 1-27, 28-35, 
36-52, and 64-75 linked by intermolecular disulphide bonds 
(Fig. 1). This bitistatin amino acid sequence lacks the N-ter-
minal valine [32], most probably due to the action of an ami-
noexopeptidase activity in the venom batch from which the 
disintegrin was isolated. N-terminally truncated bitistatin iso-
forms have been reported previously [21]. 
To further define its disulphide bridge pattern, bitistatin 
was degraded with oxalic acid. Using this chemical cleavage 
method, Bauer et al. were able to confirm the four disulphide 
bonds of echistatin [28] and we established the disulphide 
bridge pat tern of eristostatin [18]. Degradation with oxalic 
acid produces a mixture of fragments, which included incom-
plete series of disulphide-bonded peptides such as (abCdef)-S-
S-(ghiCjklm); (bCdef)-S-S-(ghiCjklm) ; (bCdef)-S-S-(iCjklm); 
(Cde)-S-S-(iCjk), etc. Occurrence of dehydration has also 
been reported [27] and thus the mixture of peptides may in-
clude native fragments (M) along with dehydrated (M-18 Da) 
fragments. Hence, reversed-phase H P L C separation of such 
fragment mixtures yields few pure peptide fractions and a 
broad asymmetric peak formed by the continuous distribution 
of multiple, partially resolved subpeaks. Twenty-three H P L C 
fractions were collected and initially characterised by M A L D I 
T O F mass spectrometry. The computer program D I S U L -
P H I D E [30] was employed to calculate all combinations of 
two disulphide-bonded peptides matching the mass data. Gen-
erally, a large number of combinations of peptides containing 
different cysteine residues were theoretically possible for each 
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SPPVgGNKILEEGEEgDgGSPMICQDRCCNAATgKLTPGSQgKIHGE^TOSKFKKAGTVgRIARGDWNDDYgTGKSSDCPWHN 
-TPCK-Trypsin 
- reversed-phase HPLC 
1SPPVCGNKILEEGEECDCGSPASCQDR2 ' 
8CCNAATCK35 
5LTPGSQCNHGECCDQCK52 
5GDWNDDYCTGK75 
Fig. 1. The amino acid sequence of bitistatin and the two major tryptic products isolated by reversed-phase HPLC and characterised by N-ter-
minal sequencing and amino acid analysis. S-S, disulphide bond; (S-S)n indicates that the four fragments of F2 are linked by 'n' inter- and in-
trachain disulphide bonds. 
quasimolecular ion (M+H+). Therefore, the assignment was 
filtered using compositional data gathered from amino acid 
analysis. In addition, those fractions containing a major qua-
simolecular ion (M+H+) were subjected to N-terminal amino 
acid sequence analysis. 
HPLC fraction Bl contained a fragment whose molecular 
mass (569 Da) and amino acid composition are compatible 
only with (18CGS20)-S-S-(29CNA31) (Fig. 2). 
Chromatographie fraction B3 contained a major ion of mo-
lecular mass 769 Da. Amino acid sequence analysis showed 
(S,A), (D,G), T, V. These data identified a disulphide bond 
between peptides 56AGTVC60 and 77SDC79 (Mcaicuiated : 770 
Da), and confirmed cystine Cys60-Cys79. Minor ions in frac-
tion B3 were subjected to collision-induced fragmentation 
analysis. Two ions with monoisotopic molecular masses 
777.5 and 778.5 Da were unequivocally characterised as dehy-
drated fragment 20-25 (SPANCQ-OH) disulphide-linked to 
CG. The mass difference of 1 Da suggest partial deamidation 
of Asn23 or Gin25, most probably during hydrolysis with ox-
alic acid. Another ion in B3 with monoisotopic mass: 893.1 
Da corresponded to either 20SPANCQ25 disulphide-bonded to 
18 C G N 20 o r t Q ( 2 0 S p A N C Q D _ O H 2 6 ) _ S _ S _ ( C G ) T h e d i p e p t i d e 
CG occurs twice in the bitistatin sequence (positions 5-6 and 
18-19), restricting thus the linkage possibilities of cysteine 24 
to Cys5 or Cys18. 
HPLC fractions B8-B10 displayed a major ion at 912 Da. 
Twenty-seven possibilities were assigned using DISUL-
PHIDE, including disulphide bridge combinations between 
cysteines 5-16, 5-34, 5^4-2, 5-51, 5-72, 5-79, 16-18, 16-34, 
16-60, 24-34, 24^12, 24-^8, 24-51, 24-72, 28^12, 28-79, 34-
42, 34^17, 34-51, 47-79, and 60-79. N-terminal sequence 
analysis of B8 clearly showed that the actual fragment was 
(13GEEC16)-S-S-(31AATC34) (Mcalculated : 912 Da) (Fig. 2). 
Furthermore, HPLC fractions Bl l and B12 displayed a mix-
ture of major ions with molecular masses 1301 and 1532 Da, 
and minor ions at 1170 and 1320 Da. The former ion was the 
major component in fraction B13-B14. Each of these masses 
can potentially correspond to a large number of different di-
sulphide bond combinations. However, amino acid analysis 
demonstrated the presence of equimolar amounts of histidine 
and tyrosine. Since these two amino acids occur only twice 
and once, respectively, in the amino acid sequence of bitistatin 
(Fig. 1), the compositional and mass spectroscopic data to-
gether unambiguously identified fragment (44HGEC47)-S-S-
(65GDWNDDYCT73) (Mcalculated : 1531 Da) (Fig. 2). On the 
other hand, N-terminal amino acid sequence analysis of frac-
tion B12 showed that the ion with molecular mass 1320 Da 
may correspond to (58TVCRIA63)-S-S-(79CPWHN83) 
(^calculated: 1319 Da) and the ion at 1301 Da may be a dehy-
drated product of this fragment (Fig. 2). These assignments 
were further confirmed by mass spectrometric analysis of frac-
tions B11-B13 after reduction with 2-mercaptoethanol. In ad-
dition, the ion with mass 1170 Da could be assigned to disul-
phide-bonded peptides 32ATCKLTP38 (733 Da) and 
13GEEC16 (437 Da). 
Finally, 10 cycles of N-terminal sequence analysis of frac-
tion B17 (major ion of 1655 Da) yielded (P,A,G) (P,A,T,E), 
(V,N,E), K, (G,L), (N,T), (K,P), I, L, E. These data indicated 
that B17 contained a mixture of (2PPVCGNKILEEG14)-S-S-
(21PANC24) (Mcaicuiated: 1655 Da) and (13GEEC16)-S-S-
(32ATCKLTP38). The structure of the former fragment was 
unambiguously determined by MS/MS analysis of the mono-
isotopic 1655 Da ion. These results established, therefore, the 
disulphide bond between Cys5 and Cys24 and confirmed the 
linkage Cys16-Cys34 (Fig. 2). The Cys5-Cys24 linkage was fur-
ther demonstrated by MS/MS analysis of the major ion in 
1 5 16 18 24 2829 34 42 4748 51 60 72 19 83 
SPWCGNKILEEGEECDÇGSPANÇQDRœNAATCKLTPGSQOmGEŒ 
!-S-S(Bl:569 Da)- - S-S (Bll: 1531 Da) 
S-S (B3: 893 Da) | s-S —-| 
(Bll: 1068 Da) 
- S-S (B17: 1655 Da) -| 
- S-S (B8: 912 Da) — 
- S-S (B12: 1170 Da) 
- S-S (B3: 770 Da) 
— I 
— S-S (B12: 1301 Da) -
S-S (B20: 2318 Da) 
S-S (B20: 2546 Da) 
Fig. 2. Alignment of disulphide-bonded peptides characterised by combination of MALDI and electrospray ionization MS/MS mass spectrome-
try, N-terminal sequencing, and amino acid analysis of oxalic acid-derived fragments separated by reversed-phase HPLC. S-S, disulphide bond; 
B-, nomenclature for HPLC fractions. Experimentally measured molecular masses are indicated. The N- and C-terminal residues and the 14 
cysteines of bitistatin are numbered. Cysteine residues are double underlined. 
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5 16 IB 24 2829 34 42 4748 51 60 72 79 
Bitistatin: sppvcqnkileeGEECDCGSPANcqdRCCNAATCKLTPGSQCNHGECCDQCKFKKAGTVCRIARGDWNDDYCTGKSSDCPWNH 
S S S — S S S 
Albolabrin: EAGEDCDCGSPAN- -PCCDAATCKLL PGAOCGEGLCCDQCS FMKKGTICRRARGDDLDDYCNGISAGC PRNPLHA 
Kistrin : 
Flavoridin: 
Eristostatin: 
Echistatin: 
GKECDCSSPEN PCCDAATCKLRPGAQCGEGLCCEQCKFSRAGKICRIPRGDMPDDRCTSQSADCPRTH 
GEECDCGSPSW PCCDAATCKLRPGAQCADGLCCDQCRFKKKTGICRIARGDFPDDRCTGLSNDCPRWNDL 
I I ¡I I I — I l 
QEEPCATGPCCRRCKFKRAGKVCRVARGDWNDDYCTGKSCDCPRNPWN 
ECESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT 
Fig. 3. Comparison of the disulphide bridge patterns of bitistatin (this work), albolabrin [12,13], kistrin [10], flavoridin [11], eristostatin [18], 
and echistatin [7-9]. Amino acid residues of bitistatin absent in the primary structures of flavoridin and kistrin are shown in lower case. 
fraction B18 (1540 Da), which corresponded to the dehy-
drated variant of the 1655 Da structure: (2PPVCGNKILEE-
G14-OH)-S-S-(22ANC24). 
Our results provide direct evidence for disulphide bridges 
between Cys5-Cys24, Cys16-Cys34, Cys18-Cys29, Cys47-Cys72, 
and Cys60-Cys79. The four remaining cysteines of bitistatin 
(Cys28, Cys42, Cys48, and Cys51) can potentially form three 
different disulphide bond combinations. Mass spectrometric 
analysis of fraction B20 yielded two prominent ions with mo-
lecular masses 2319 and 2546 Da. Amino acid analysis of this 
fraction showed histidine and tyrosine, indicating the presence 
of a fragment containing most probably Cys72, which is the C-
terminal residue of the single tyrosine of bitistatin (Fig. 1). 
However, no combination of two peptides joined by the single 
disulphide bond Cys47-Cys72 matches the experimental data. 
Thus, we searched for possible combinations of peptides in-
cluding the minimal amino acid sequences containing tyrosine 
and histidine and joined by Cys47-Cys72 (44HGEC47 and 
71YC72) and extended them from either termini to include a 
second disulphide bond. The only solutions found were the 
structurally related fragments (37TPGSQCNHGECC48)-S-S-
(65GDWNDDYCT73) (Mcaicuiated : 2318 Da) and (36LTPGSQ-
CNHGECCD49)-S-S-(65GDWNDDYCT73) (Mcalculated : 2546 
Da) (Fig. 2). B20 displayed a complex mixture of 5-6 N-ter-
minal sequences, including those compatible with our frag-
ment assignment. Another ion tentatively assigned to frag-
ments joined by a disulphide linkage between Cys42 and 
Cys48: (37TPGSQCN43)-S-S-(48CDQ50) was 1068 Da found 
in fraction Bll (Fig. 2). As a whole, these data provided 
strong circumstantial evidence for the existence of a disul-
phide bridge between Cys42 and Cys48, and suggested that 
the seventh, non-experimentally assigned disulphide bond of 
bitistatin involves Cys28 and Cys51 (Fig. 2). 
Previous protein chemical and structural studies have 
shown that disintegrins exhibit three different disulphide 
bridge (S-S) patterns: S-S(I), albolabrin [12,13]; S-S(II), kis-
trin and flavoridin [10,11,25]; and S-S(III), echistatin and eri-
stostatin [7-9,18,25]. Our results show that the conserved cys-
teine residues of bitistatin adopts disulphide bridge pattern S-
S(II) and that Cys5 and Cys24, which are only found in bitis-
tatin, form an extra disulphide bond (Fig. 3). Disulphide bond 
patterns I and II share three disulphides and differ in another 
three cystines (Fig. 3). Using the program DISULPHIDE we 
calculated all theoretical combinations of two disulphide-
bonded peptides for the MALDI ions whose molecular masses 
were measured in different HPLC fractions but which had not 
been used for disulphide bond assignment. All possible link-
age combinations were found except for the following pair-
ings: Cys24-Cys28, Cys16-Cys47, Cys18-Cys47, Cys28-Cys47, 
Fig. 4. Stereo drawings of molecular models of bitistatin constructed 
using the three-dimensional structures of flavoridin (A) or kistrin 
(B) as templates, outlining the possible disposition of bitistatin's ex-
tra loop in relation to the RGD-containing loop. Inserted polypep-
tide stretches (SI-El2 and C24-D26, see Fig. 3) are shown as thick 
lines. C5, C24, cysteine residues at positions 5 and 24, respectively, 
which form a disulphide bond found in bitistatin but are absent in 
other disintegrin molecules (Fig. 3). 
J.J. Calvete et al.lFEBS Letters 416 (1997) 197-202 201 
Cys29-Cys47, Cys51-Cys47, Cys28-Cys48, Cys29-Cys48, Cys29-
Cys60, Cys48-Cys51, and Cys18-Cys72. Thus, all the experimen-
tal data are compatible with the proposed disulphide bond 
pattern type II for bitistatin (Fig. 3). Furthermore, there is 
a lack of evidence for the albolabrin (type I)-specific disul-
phide bond between Cys47-Cys51. 
3.2. Possible structure-function correlations 
Realisation of the structural constraints imposed by the 
additional Cys5-Cys24 linkage of bitistatin awaits the resolu-
tion of the structure of the disintegrin. However, the large 
primary structure conservation among disintegrins and the 
fact that bitistatin shares cystine linkages with kistrin and 
flavoridin, two disintegrins with known NMR solution struc-
ture [10,11], provide templates for the elaboration of a molec-
ular model of bitistatin. Bitistatin contains a 11-13-residue N-
terminal extension and a sequence of three amino acids 
(24CQD26) which are absent in medium-long disintegrins, i.e. 
flavoridin and kistrin (shown in lower case in Fig. 3). These 
extra polypeptide stretches are linked by disulphide bond 
Cys5-Cys24. Modelling of bitistatin, taking the NMR structure 
of flavoridin [11] (PDB accession code: 1FVL) as template 
(Fig. 4A), would suggest that the extra loop is located oppo-
site to the RGD-containing loop, too far away to influence 
the conformation or binding activity of the active loop (Fig. 
4A). However, if the molecular model of bitistatin is con-
structed with the three-dimensional structure of kistrin [10] 
(PDB accession code: IKST), the extra Cys5-Cys24 loop of 
bitistatin would depart from the protein core from the same 
side as the RGD-containing loop and could potentially alter 
the spatial orientation or accessibility of the RGD loop, and/ 
or create another recognition surface in the bitistatin molecule 
(Fig. 4B). In this respect, it is worth to mention that bitistatin 
and eristostatin, which (except for a Ile/Val substitution) have 
the same RGD loop structure (Fig. 3) and integrin receptor 
selectivity, differ however significantly in their platelet aggre-
gation inhibitory potency [17,20]. Plausible explanations are: 
(a) the existence of an additional disulphide bridge between 
Cys14-Cys40 of eristostatin (Fig. 3) imposes structural con-
strains to the RGD loop enhancing its integrin binding affin-
ity; and (b) the Cys5-Cys24 loop of bitistatin (as modelled 
using the coordinates of kistrin, Fig. 4B) influences the acces-
sibility of the RGD sequence for binding to its integrin recep-
tor. The first possibility would be in accordance with the 
hypothesis that the dynamical behaviour of RGD loops may 
serve as determinants of binding kinetics and affinity [33,34]. 
On the other hand, although both eristostatin and bitistatin 
are poor inhibitors of the adhesion of human umbilical vein 
endothelial cells (HUVEC) to immobilised vitronectin, HU-
VEC adhere very well to immobilised bitistatin but not at all 
to immobilised eristostatin [35]. These authors showed that 
the inability of these disintegrins to inhibit HUVEC adhesion 
to vitronectin correlated with their inability to bind to purified 
vitronectin receptor (av^), a n d have suggested that perhaps 
HUVEC adhesion to bitistatin is mediated by a receptor other 
than cCyß3. The hypothesis that bitistatin's N-terminal Cys5-
Cys24 loop is involved in the proposed interaction with HU-
VEC deserves further work. 
The precursors of a group of haemorrhagic snake venom 
metalloproteinases (SVMP) from Crotalid snakes display a 
multidomain structure and have been organised into four 
classes (PI-PIV) according to the domain structure of the 
processed products (reviewed in [36,37]). PI and PII SVMP 
precursors contain pre, pro, Zn-proteinase, spacer, and disin-
tegrin domains, and the individual domains are released by 
proteolytic processing. On the other hand, classes PHI and IV 
SVMP contain a disintegrin-like domain in which the RGD 
sequence has been replaced with ECD. This disintegrin-like 
domain is preceded by a spacer region containing two cysteine 
residues not found in the homologous region of PI and PII 
classes, and is followed by a cysteine-rich domain (100-130 
residues, 13 absolutely conserved cysteines). PIV SVMPs con-
tain, in addition, C-terminal lectin-like domains. The spacer, 
disintegrin-like, and cysteine-rich domains remain together 
(through disulphide bonds) in mature PHI and PIV SVMPs. 
A family of homologues of snake venom metalloproteinases 
(termed the ADAMs, for a disintegrin-like and metallopro-
teinase-containing protein [38]) has been described from a 
variety of organisms including mammals, reptiles and inverte-
brates [39]. In addition to the domain structure described for 
PHI SVMPs, the ADAMs have an epidermal growth factor-
like domain, a transmembrane segment, and a cytoplasmic 
tail. It is noteworthy that the largest amino acid sequence 
similarity between the spacer and disintegrin-like domains of 
PIII/IV SVMPs and the ADAMs and RGD-containing disin-
tegrins is with bitistatin (i.e. 45.7%/60.2% sequence identity/ 
similarity between bitistatin and the disintegrin-like domain of 
mammalian epididymal protein EAP-I [40]) and the positions 
of all 14 cysteines of bitistatin are conserved. Our data pro-
vide a model for the disulphide bond pattern of the spacer/ 
disintegrin-like regions of class PIII/IV SVMPs and ADAMs. 
The extra cysteine, which provides the disintegrin-like domain 
of PHI SVMPs and ADAMs with an odd number of cys-
teines, may be free or may form a disulphide bond with a 
cysteine in the cysteine-rich domain, which also contains an 
odd number of cysteine residues. 
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